Intraocular tuberculosis

Ocular Immunology and Inflammation

Volumn 18, Issue 4, 2010, Pages 281-291

  Cutrufello, Nicholas J ^a   Karakousis, Petros C ^b   Fishler, Jane ^a   Albini, Thomas A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; IFN release assays (IGRA); Lipoarabinomannan (LAM); Ocular tuberculosis' PCR

Indexed keywords

CORTICOSTEROID; CULTURE FILTRATE PROTEIN 10; CYANOCOBALAMIN; EARLY SECRETORY ANTIGENIC TARGET 6; ESTROGEN; ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; NEUROMUSCULAR BLOCKING AGENT; PREDNISONE; PYRAZINAMIDE; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; WARFARIN;

ANTIGEN DETECTION; ASSAY; BACTERIUM CULTURE; BLEPHAROSPASM; CENTRAL SCOTOMA; CLINICAL TRIAL; COLOR VISION; COLOR VISION DEFECT; COMPARATIVE STUDY; COUNSELING; DIAGNOSTIC ACCURACY; DISEASE TRANSMISSION; DRUG EFFECT; DRUG SENSITIVITY; DRUG SUBSTITUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPIPHORA; EYE EDEMA; EYE EXAMINATION; GAMMA INTERFERON RELEASE ASSAY; GENETIC ANALYSIS; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL PROCEDURES; IMMUNOTHERAPY; INCIDENCE; LIVER TOXICITY; LYMPHADENOPATHY; NONHUMAN; OCULAR TUBERCULOSIS; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; OPTIC NEURITIS; OUTCOME ASSESSMENT; PARACENTESIS; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHLYCTENULAR KERATITIS; PHOTOPHOBIA; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SCLERITIS; SENSITIVITY AND SPECIFICITY; STAINING; THORAX RADIOGRAPHY; TUBERCULIN TEST; UVEITIS; VISUAL ACUITY; VISUAL FIELD; VITREOUS BIOPSY;

ADRENAL CORTEX HORMONES; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA; MALE; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; TUBERCULOSIS, OCULAR;

EID: 77954882238     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2010.489729     Document Type: Review

References (114)

1. World Health Organization (WHO). Frequently asked questions about TB and HIV. 2010; www.who.int/tb/challenges/ hiv/faq/en/index.html. Accessed 2010.
2. WHO REPORT 2009 Global Tuberculosis Control [Onlineö. 2009; apps.who.int/globalatlas/predefinedreports/tb/ PDF-Files/usa.pdf. Accessed October 4, 2009.
3. Das D, Biswas J, Ganesh SK. Pattern of uveitis in a referral uveitis clinic in India. Indian J Ophthalmol. 1995;43(3): 117-121.
4. Singh R GV, Gupta A. Patterns of uveitis in a Referral eye clinic in North India. Indian J Ophthalmol. 2004 2004;52: 121-125.
5. Biswas J, Madhavan HN, Gopal L, Badrinath SS. Intraocular tuberculosis: clinicopathologic study of five cases. Retina. 1995;15(6):461-468.
6. Lal B, Gupta RK. Ocular involvement in tuberculosis: a clinical study. Afro-Asian J Ophthalmol. 1985;4:241-243.
7. Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol. 1987;103(2):131-136.
8. Abrahams IW, Jiang YQ. Ophthalmology in China: endogenous uveitis in a Chinese ophthalmological clinic. Arch Ophthalmol. 1986;104(3):444-446.
9. Mercanti A, Parolini B, Bonora A, Lequaglie Q, Tomazzoli L. Epidemiology of endogenous uveitis in northeastern Italy: analysis of 655 new cases. Acta Ophthalmol Scand. 2001;79(1):64-68.
10. Wakabayashi T, Morimura Y, Miyamoto Y, Okada AA. Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm. 2003;11(4):277-286.
11. Islam SM, Tabbara KF. Causes of uveitis at the Eye Center in Saudi Arabia: a retrospective review. Ophthalmic Epidemiol. 2002;9(4):239-249.
12. Donahue HC. Ophthalmologic experience in a tuberculosis sanatorium. Am J Ophthalmol. 1967;64(4):742-748.
13. Chu AD, Polesky AH, Bhatia G, Bush TM. Active and latent tuberculosis in patients with systemic lupus erythematosus living in the United States. J Clin Rheumatol. 2009;15(5): 226-229.
14. Mengoli C CE, Tognon M, Sattin A. Ocular tuberculosis in padua in the period 2004-2008: clinical and epidemiological aspects. ICAAC abstract. 2009.
15. Biswas J, Badrinath SS. Ocular morbidity in patients with active systemic tuberculosis. Int Ophthalmol. 1995;19(5): 293-298.
16. Mooney AJ. Some ocular sequelae of tuberculous meningitis; a preliminary survey, 1953-1954. Am J Ophthalmol. 1956;41(5):753-768.
17. Verma BM, Sriwastava SK, Srivastava JR. Ocular manifestations of tubercular meningitis and their prognostic value in children. Indian J Ophthalmol. 1981;29(3):301-302.
18. Koch R. Die Aetiologie der Tuberkulose. Berlin Klin. Wochenschrif. 1882;19:221-230.
19. Friedberg DM, Lorenzo-Latkany M. Ocular Complications. In: Rom WN, Garay SM, eds. Tuberculosis, 2nd Ed. Philadelphia: Lippincott Williams & Wilkins; 2004: 465-476.
20. Buckner CB, Leithiser RE, Walker CW, Allison JW. The changing epidemiology of tuberculosis and other mycobacterial infections in the United States: implications for the radiologist. AJR Am J Roentgenol. 1991;156(2):255-264.
21. Karakousis PC, Yoshimatsu T, Lamichhane G, et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med. 2004;200(5):647-657.
22. Johnson MD, Decker CF. Tuberculosis and HIV infection. Dis Mon. 2006;52(11-12):420-427.
23. Moreno S, Miralles P, Diaz MD, et al. Isoniazid preventive therapy in human immunodeficiency virus-infected persons: long-term effect on development of tuberculosis and survival. Arch Intern Med. 1997;157(15):1729-1734.
24. Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol. 2008;59(3):363-380; quiz 382-1364
25. CDC. Tuberculosis in the United States, 1981-1984. In: Department of Health and Human Services CfDCaP, ed1986.
26. Surveillance of tuberculosis and AIDS co-morbidity- Florida, 1981-1993. MMWR Morb Mortal Wkly Rep. 19 Jan 1996;45(2):38-41.
27. Tuberculosis-United States, 1981. MMWR Morb Mortal Wkly Rep. 20 Aug 1982;31(32):443-446.
28. CDC.. Trends in tuberculosis morbidity-United States, 1992-2002. MMWR Morb Mortal Wkly Rep. 2003;520 (11):217-222.
29. Tuberculosis morbidity-United States, 1995. MMWR Morb Mortal Wkly Rep. 10 May 1996;45(18):365-370.
30. Tuberculosis morbidity-United States, 1996. MMWR Morb Mortal Wkly Rep. 1 Aug 1997;46(30):695-700.
31. Tuberculosis morbidity-United States, 1997. MMWR Morb Mortal Wkly Rep. 10 Apr 1998;47(13):253-257.
32. Harries AD. Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet. 1990;335(8686):387-390.
33. Babu RB, Sudharshan S, Kumarasamy N, Therese L, Biswas J. Ocular tuberculosis in acquired immunodeficiency syndrome. Am J Ophthalmol. 2006;142(3):413-418.
34. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-683.
35. Mehta S, Gilada IS. Ocular tuberculosis in acquired immune deficiency syndrome (AIDS). Ocul Immunol Inflamm. 2005;13(1):87-89.
36. Shimakawa M. Choroidal tuberculoma in a patient with acquired immunodeficiency syndrome. Jpn J Ophthalmol. 2000;44(6):697.
37. Sheu SJ, Shyu JS, Chen LM, Chen YY, Chirn SC, Wang JS. Ocular manifestations of tuberculosis. Ophthalmology. 2001;108(9):1580-1585.
38. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993;22(6):1154-1158.
39. Garip A, Diedrichs-Mohring M, Thurau SR, Deeg CA, Wildner G. Uveitis in a patient treated with Bacille-Calmette- Guerin: possible antigenic mimicry of mycobacterial and retinal antigens. Ophthalmology. 2009;116(12):2457-2462 e2451-2452.
40. Spratt A, Key T, Vivian AJ. Chronic anterior uveitis following bacille Calmette-Guerin vaccination: molecular mimicry in action? J Pediatr Ophthalmol Strabismus. 2008;45(4): 252-253.
41. Gupta A, Gupta V. Tubercular posterior uveitis. Int Ophthalmol Clin. 2005;45(2):71-88.
42. Alvarez S, McCabe WR. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine (Baltimore). 1984;63(1):25-55.
43. Varma D, Anand S, Reddy AR, et al. Tuberculosis: an underdiagnosed aetiological agent in uveitis with an effective treatment. Eye (Lond). 2006;20(9):1068-1073.
44. Morimura Y, Okada AA, Kawahara S, et al. Tuberculin skin testing in uveitis patients and treatment of presumed intraocular tuberculosis in Japan. Ophthalmology. 2002;109(5):851-857.
45. Bansal R, Gupta A, Gupta V, Dogra MR, Bambery P, Arora SK. Role of anti-tubercular therapy in uveitis with latent/manifest tuberculosis. Am J Ophthalmol. 2008;146(5): 772-779.
46. Rosen PH, Spalton DJ, Graham EM. Intraocular tuberculosis. Eye. 1990;4 (Pt 3):486-492.
47. Demirci H, Shields CL, Shields JA, Eagle RC Jr. Ocular tuberculosis masquerading as ocular tumors. Surv Ophthalmol. 2004;49(1):78-89.
48. Tabbara KF. Ocular tuberculosis: anterior segment. Int Ophthalmol Clin. 2005;45(2):57-69.
49. Stechschulte SU, Kim RY, Cunningham ET Jr. Tuberculous neuroretinitis. J Neuroophthalmol. 1999;19(3):201-204.
50. Gupta V, Gupta A, Rao NA.. Intraocular tuberculosis: an update. Surv Ophthalmol. 2007;52(6):561-587.
51. Croxatto JO, Mestre C, Puente S, Gonzalez G. Nonreactive tuberculosis in a patient with acquired immune deficiency syndrome. Am J Ophthalmol. 1986;102(5):659-660.
52. Barondes MJ, Sponsel WE, Stevens TS, Plotnik RD. Tuberculous choroiditis diagnosed by chorioretinal endobiopsy. Am J Ophthalmol. 1991;112(4):460-461.
53. Wolfensberger TJ, Piguet B, Herbort CP. Indocyanine green angiographic features in tuberculous chorioretinitis. Am J Ophthalmol. 1999;127(3):350-353.
54. DiLoreto DA, Jr., Rao NA.. Solitary nonreactive choroidal tuberculoma in a patient with acquired immune deficiency syndrome. Am J Ophthalmol. 2001;131(1): 138-140.
55. Gupta V, Gupta A, Arora S, Bambery P, Dogra MR, Agarwal A. Presumed tubercular serpiginouslike choroiditis: clinical presentations and management. Ophthalmology. 2003;110(9):1744-1749.
56. Rao NA, Saraswathy S, Smith RE. Tuberculous uveitis: distribution of Mycobacterium tuberculosis in the retinal pigment epithelium. Arch Ophthalmol. 2006;124(12):1777-1779.
57. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S. Eales disease: an update. Surv Ophthalmol. 2002;47(3):197-214.
58. Bodaghi B, LeHoang P. Ocular tuberculosis. Curr Opin Ophthalmol. 2000;11(6):443-448.
59. Gupta A, Gupta V, Arora S, Dogra MR, Bambery P. PCRpositive tubercular retinal vasculitis: clinical characteristics and management. Retina. 2001;21(5):435-444.
60. Gupta A, Bansal R, Gupta V, Sharma A, Bambery P. Ocular signs predictive of tubercular uveitis. Am J Ophthalmol. Feb 9 2010.
61. Kurup SK, Buggage RR, Clarke GL, Ursea R, Lim WK, Nussenblatt RB. Gamma interferon assay as an alternative to PPD skin testing in selected patients with granulomatous intraocular inflammatory disease. Can J Ophthalmol. 2006;41(6):737-740.
62. Alvarez GG, Roth VR, Hodge W. Ocular tuberculosis: diagnostic and treatment challenges. Int J Infect Dis. 2009;13(4):432-435.
63. Schlaegel TF Jr. Differential diagnosis. Int Ophthalmol Clin. 1977;17(3):233-246.
64. Vasconcelos-Santos DV, Zierhut M, Rao NA. Strengths and weaknesses of diagnostic tools for tuberculous uveitis. Ocul Immunol Inflamm. 2009;17(5):351-355.
65. Lee KS, Hwang JW, Chung MP, Kim H, Kwon OJ. Utility of CT in the evaluation of pulmonary tuberculosis in patients without AIDS. Chest. 1996;110(4):977-984.
66. Bakheet SM, Powe J, Ezzat A, Rostom A. F-18-FDG uptake in tuberculosis. Clin Nucl Med. 1998;23(11):739-742.
67. Mantoux: Tuberculin skin test. 2003; http://www.cdc.gov/ tb/education/Mantoux/images/mantoux.pdf. Accessed October 13, 2009.
68. Long R. The Canadian Lung Association/Canadian Thoracic Society and Tuberculosis Prevention and Control. Can Respir J. 2007;14(7):427-431.
69. Abrams J, Schlaegel TF, Jr. The tuberculin skin test in the diagnosis of tuberculous uveitis. Am J Ophthalmol. 1983;96(3):295-298.
70. Rosenbaum JT, Wernick R. The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tuberculosis: a Bayesian analysis. Arch Ophthalmol. 1990;108(9):1291-1293.
71. Ariga H, Harada N. [Evolution of IGRA researchesö. Kekkaku. 2008;83(9):641-652.
72. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 16 Dec 2005;54(RR-15):49-55.
73. Pai M, Zwerling A, Menzies D. Systematic review: T-cellbased assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177-184.
74. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008;177(10):1164-1170.
75. Albini TA, Karakousis PC, Rao NA. Interferon-gamma release assays in the diagnosis of tuberculous uveitis. Am J Ophthalmol. 2008;146(4):486-488.
76. Babu K, Satish V, Satish S, Subbakrishna DK, Abraham MP, Murthy KR. Utility of QuantiFERON TB gold test in a south Indian patient population of ocular inflammation. Indian J Ophthalmol. 2009;57(6):427-430.
77. Ang M, Htoon HM, Chee SP. Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay. Ophthalmology. 2009;116(7):1391-1396.
78. Cordero-Coma M, Calleja S, Torres HE, et al. The value of an immune response to Mycobacterium tuberculosis in patients with chronic posterior uveitis revisited: utility of the new IGRAs. Eye (Lond). 2010;24(1):36-43.
79. Itty S, Bakri SJ, Pulido JS, et al. Initial results of QuantiFERON- TB gold testing in patients with uveitis. Eye (Lond). 2009;23(4):904-909.
80. Mackensen F, Becker MD, Wiehler U, Max R, Dalpke A, Zimmermann S. QuantiFERON TB-Gold: a new test strengthening long-suspected tuberculous involvement in serpiginous-like choroiditis. Am J Ophthalmol. 2008;146(5):761-766.
81. Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS. 2002;16(17):2285-2293.
82. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cellbased test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J. 2006;28(1): 31-34. (Pubitemid 44914257)
83. Passalent L, Khan K, Richardson R, Wang J, Dedier H, Gardam M. Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT. TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol. 2007;2(1):68-73.
84. Mutetwa R, Boehme C, Dimairo M, et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis. 2009;13(10):1253-1259.
85. Daley P, Michael JS, Hmar P, et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis. 2009;13(8): 989-995.
86. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess. 2007;11(3):1-196.
87. Arora SK, Gupta V, Gupta A, Bambery P, Kapoor GS, Sehgal S. Diagnostic efficacy of polymerase chain reaction in granulomatous uveitis. Tuber Lung Dis. 1999;79(4):229-233.
88. Parashar D, Chauhan DS, Sharma VD, Katoch VM. Applications of real-time PCR technology to mycobacterial research. Indian J Med Res. 2006;124(4):385-398.
89. Therese KL, Jayanthi U, Madhavan HN. Application of nested polymerase chain reaction (nPCR) using MPB 64 gene primers to detect Mycobacterium tuberculosis DNA in clinical specimens from extrapulmonary tuberculosis patients. Indian J Med Res. 2005;122(2):165-170.
90. Biswas J, Kumar SK, Rupauliha P, Misra S, Bharadwaj I, Therese L. Detection of Mycobacterium tuberculosis by nested polymerase chain reaction in a case of subconjunctival tuberculosis. Cornea. 2002;21(1):123-125.
91. Madhavan HN, Therese KL, Gunisha P, Jayanthi U, Biswas J. Polymerase chain reaction for detection of Mycobacterium tuberculosis in epiretinal membrane in Eales' disease. Invest Ophthalmol Vis Sci. 2000;41(3):822-825.
92. Das S, Paramasivan CN, Lowrie DB, Prabhakar R, Narayanan PR. IS6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, south India. Tuber Lung Dis. 1995;76(6):550-554.
93. Biswas J, Shome D. Choroidal tubercles in disseminated tuberculosis diagnosed by the polymerase chain reaction of aqueous humor: a case report and review of the literature. Ocul Immunol Inflamm. 2002;10(4):293-298.
94. Horsburgh CR, Jr., Feldman S, Ridzon R. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis. 2000;31(3):633-639.
95. Hamade IH, Tabbara KF. Complications of presumed ocular tuberculosis. Acta Ophthalmol. 22 Jun 2009. [Epub ahead of printö
96. Prasad K, Volmink J, Menon GR. Steroids for treating tuberculous meningitis. Cochrane Database Syst Rev. 2000(3):CD002244.
97. Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis. 1997;25(4):872-887.
98. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741-1751.
99. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2002(4):CD000526.
100. Cunha B. Pulmonary tuberculosis and steroids. Chest. 1995;107:1486-1487.
101. Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat Med. 1998;4(1): 92-96.
102. Herr AS, Wochnik GM, Rosenhagen MC, Holsboer F, Rein T. Rifampicin is not an activator of glucocorticoid receptor. Mol Pharmacol. 2000;57(4):732-737.
103. Rathinam SR, Lalitha P. Paradoxical worsening of ocular tuberculosis in HIV patients after antiretroviral therapy. Eye. 2007;21(5):667-668.
104. Menon V, Jain D, Saxena R, Sood R. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol. 2009;93(9):1251-1254.
105. Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. Mayo Clin Proc. 2003;78(11):1409-1411.
106. Kumar A, Sandramouli S, Verma L, Tewari HK, Khosla PK. Ocular ethambutol toxicity: is it reversible? J Clin Neuroophthalmol. 1993;13(1):15-17.
107. Visser ME, Texeira-Swiegelaar C, Maartens G. The shortterm effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2004;8(2):260-262.
108. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192-202.
109. Tabbara KF. Tuberculosis. Curr Opin Ophthalmol. 2007;18(6):493-501.
110. Skolik S, Willermain F, Caspers LE. Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis. Ocul Immunol Inflamm. 2005;13(6):483-485.
111. Fineman MS, Vander J, Regillo CD, Fineman SW, Brown GC. Hypopyon uveitis in immunocompetent patients treated for Mycobacterium avium complex pulmonary infection with rifabutin. Retina. 2001;21(5):531-533.
112. Bhagat N, Read RW, Rao NA, Smith RE, Chong LP. Rifabutin- associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Ophthalmology. 2001;108(4):750-752.
113. Rao NA, Albini TA, Kumaradas M, Pinn ML, Fraig MM, Karakousis PC. Experimental ocular tuberculosis in guinea pigs. Arch Ophthalmol. 2009;127(9):1162-1166.
114. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician. 2005;72(9):1761-1768.